A major shift is expected in India’s diabetes and obesity treatment market as the patent for semaglutide expires on March 20, 2026. The loss of exclusivity for the GLP-1 receptor agonist, originally developed by Novo Nordisk and marketed globally as Ozempic and Wegovy, is likely to trigger the launch of a large number of branded generics across the country. Industry observers anticipate that more than 50 branded versions of semaglutide could enter the Indian market soon after the patent protection ends. Several domestic drugmakers have reportedly been preparing for this transition by developing their own formulations in advance so they can move quickly once regulatory pathways allow commercialization.
A number of leading Indian pharmaceutical manufacturers are expected to participate in the early wave of launches. Companies such as Dr. Reddy’s Laboratories, Sun Pharmaceutical…
